DOCSLIB.ORG

Sartorius Stedim Biotech Universal Registration Document 2020 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sartorius Stedim Biotech Universal Registration Document 2020 4 Sartorius Stedim Biotech Key Figures All figures are given in millions of € according 2020 Δ in % 20197 2018 2017 2016 to the IFRS, unless otherwise specified Order intake, sales revenue and earnings Order intake 2,381.0 54.3 1,543.5 1,307.3 1,162.3 1,080.8 Sales revenue 1,910.1 32.6 1,440.6 1,212.2 1,081.0 1,051.6 Underlying EBITDA1, 2 604.7 43.5 421.5 342.4 294.9 288.7 Underlying EBITDA1, 2 as % of sales revenue 31.7 2.4 pp 29.3 28.2 27.3 27.5 Net profit after non-controlling interest 357.8 52.6 234.5 208.1 161.1 153.7 Underlying net profit1 after non-controlling interest2 383.8 45.9 263.0 219.3 180.4 176.6 Research and development costs 84.5 6.6 79.2 60.6 53.2 47.5 Financial data per share Earnings per share (in €) 3.88 52.6 2.54 2.26 1.75 1.67 Earnings per share (in €)1, 3 4.16 45.9 2.85 2.38 1.96 1.92 Dividend per share (in €) 0.684 100.0 0.34 0.57 0.46 0.42 Balance sheet Balance sheet total 3,069.3 66.3 1,845.4 1,571.5 1,403.9 1,195.8 Equity 1,482.9 24.7 1,188.9 1,044.9 879.5 763.6 Equity ratio (in %) 48.3 -16.1 pp 64.4 66.5 62.6 63.9 Financials Capital expenditures as % of sales revenue 8.3 -1.1 pp 9.4 14.6 12.6 7.6 Depreciation and amortization 100.9 38.5 72.8 60.9 50.6 44.7 Cash flow from operating activities 416.9 34.4 310.1 227.3 174.7 156.7 Net debt5 527.0 377.2 110.4 125.7 127.1 67.6 Ratio of net debt to underlying EBITDA1, 2, 6 0.8 0.5 pp 0.3 0.4 0.4 0.2 Total number of employees as of December 31 7,566 21.6 6,223 5,637 5,092 4,725 1 Adjusted for extraordinary items 2 For more information on EBITDA, net profit and the underlying presentation, please refer to the Group Business Development chapter and to the Glossary. 3 Adjusted for extraordinary items, non-cash amortization acc. to IFRS 3 and fair value adjustments of hedging instruments, as well as the corresponding tax effects for each of these items. 4 Amount suggested by the Board of Directors (Conseil d’administration) and subject to approval by the Annual General Shareholders’ Meeting. 5 Net debt excludes the liability for the remaining purchase price for acquisitions; 2020: €305.3 million euros, 2019: €72.5 million euros, 2018: €8.7 million euros, 2017: €46.5 million euros, 2016: €49.6 million euros 6 EBITDA includes underlying pro forma EBITDA of acquisitions completed in 2020 7 The figures for the reporting period 2019 were restated due to the finalization of the purchase price allocation for the acquisition of Biological Industries. Sartorius Stedim Biotech Share in Comparison to the CAC Large 60 (indexed) 700 600 500 400 300 200 100 0 2016 Sartorius Stedim Biotech CAC Large 60 2020 S i t e s i n m o r e t h a n 2 5 c o u n t r i e s , 25+ headquartered in Aubagne France >7,500 Employees ~16% Sales CAGR 2011-2020 Sales share with life ~90% science customers Change in underlying +10.8pp EBITDA margin 2011-2020 Sartorius Stedim Biotech S.A. market capitalization; listed on ~€26.8bn the CAC Large 60 Sales growth in constant currencies; underlying = excluding extraordinary items Strong Presence in All Major Biopharma Markets 17%35% 14%25% Americas Asia | Pacific 40% 69% Sales revenue EMEA Employees Innovative Solutions for Better Medications With its pioneering spirit and a profound understanding of customer requirements, Sartorius Stedim Biotech has evolved into a key partner for biopharmaceutical research and the industry. Our goal is to make complex and expensive development of biotech medicines and their production safer and more efficient. We cover the entire value-added chain of the biopharmaceutical industry and help with our products and services to ensure that novel therapies and vaccines reach the market faster and are accessible to more people worldwide. See page 18, Sartorius Stedim Biotech Group at a glance Mission At Sartorius Stedim Biotech, we empower engineers to simplify and accelerate progress in bioprocessing. In this way, we enable new and better pharmaceuticals to be manufactured and help keep medications affordable. Vision We are a magnet and dynamic platform for pioneers and leading experts in our field. We bring creative minds together for a common goal: technological breakthroughs that lead to better health for more people. Sartorius Stedim Biotech Universal Registration Document 2020 4 Universal Registration Document 2020 This Universal Registration Document has been filed on February 17, 2021, with the AMF, as competent authority under Regulation (EU) 2017/1129, without prior approval pursuant to Article 9 of the said regulation. The Universal Registration Document may be used for the purposes of an offer to the public of securities or admission of securities to trading on a regulated market if completed by a securities note and, if applicable, a summary and any amendments to the Universal Registration Document. The whole is approved by the AMF in accordance with Regulation (EU) 2017/1129. This Universal Registration Document incorporates by reference the preceding Reference Documents D. 20-0064 filed on February 17, 2020 and D.19-0060 filed on February 18, 2019. The following information is included by reference in the present Universal Registration Document: The year 2019 consolidated financial statements of Sartorius Stedim Biotech prepared using international accounting standards and the report of the statutory auditors relating to these statements, and the Group 2019 management report appearing on pages 95 to 145 and 17 to 58 respectively, of the Reference Document filed with the Autorité des Marchés Financiers on 17 February 2020, under the number D.20-0064. The year 2018 consolidated financial statements of Sartorius Stedim Biotech prepared using international accounting standards and the report of the statutory auditors relating to these statements, and the Group 2018 management report appearing on pages 90 to 137 and 18 to 56 respectively, of the Reference Document filed with the Autorité des Marchés Financiers on 18 February 2019, under the number D.19-0060. The sections of these documents not included are not of interest to an investor, and are covered in another part of this Universal Registration Document. Copies of the present Universal Registration Document can be obtained from the following: Sartorius Stedim Biotech S.A. - Z.I. Les Paluds - Avenue de Jouques CS 91051-13781 Aubagne Cedex Group website: www.sartorius.com Autorité des Marchés Financiers website: www.amf-france.org Sartorius Stedim Biotech Contents 5 Contents To Our Shareholders 7 Chairman's Message 8 Board of Directors 11 Sartorius Stedim Biotech Shares 13 Management Report 18 Structure and Management of the Group 19 Business Model, Strategy and Goals 22 Sector Conditions 26 Group Business Development 29 Net Worth and Financial Position 34 Products and Sales 38 Sustainability 41 Opportunity and Risk Report 42 Internal Control Procedures 54 Forecast Report 59 Financial Statements of the Parent Company Sartorius Stedim Biotech S.A. as of December 31, 2020 62 Corporate Governance 73 The Board of Directors and its Committees 74 Report on Corporate Governance 97 Shareholders' Meeting 103 Delegation granted for increase in capital by the Shareholders' meeting to the Board of Directors 106 Remuneration of the Members of the Board 108 Independent Auditors' Fees 122 Sartorius Stedim Biotech Contents 6 Consolidated Financial Statements and Notes 125 Statement of Profit or Loss and Other Comprehensive Income 126 Statement of Financial Position 128 Statement of Cash Flows 129 Statement of Changes in Equity 130 Notes to the Financial Statements 132 Notes to the Statement of Profit or Loss 147 Notes to the Individual Balance Sheet Items 153 Other Disclosures 183 Statutory Auditors' Report on the Consolidated Financial Statements 185 Annual Financial Statements and Notes 192 Annual Financial Statements 193 Statutory Auditors’ Report on the Financial Statements 205 Supplementary Information 210 Other Information of a Legal Nature 211 Other Information on the Assets, Financial Position and Results for the Group 222 Special Report of the Statutory Auditors on Related Party Agreements 223 Resolutions Submitted to the Annual Combined Shareholders' Meeting on March 24, 2021 225 Report of the Board of Directors 234 Information on the URD and the Annual Financial Report 242 Glossary 246 Financial Schedule 250 To Our Shareholders Sartorius Stedim Biotech To Our Shareholders Chairman's Message 9 Chairman's Message Dear Shareholders, dear Business Partners, We are currently going through extraordinary times. Our industry, the biopharma industry, is called upon to address the world's most pressing needs arising from the coronavirus pandemic. The level of effort, global collaboration and speed of progress on coronavirus vaccines and Covid-19 medications is unprecedented: Some of our customers went from mapping the coronavirus genome to delivering vaccines to patients in only nine months so biopharma has really demonstrated what it is able to achieve when it cooperates on a global scale and works at its best. It has also rewritten some implicit rules by which it used to operate. And I am convinced that many changes and lessons-learned are here to stay. In this joint effort, Sartorius Stedim Biotech is part of the solution.
Load more

Recommended publications
  • Sartorius Group 2016 Annual Report Order Intake and Sales Revenue Underlying EBITDA and Margin1) ¤ in Millions
    Sartorius Group 2016 Annual Report Order Intake and Sales Revenue Underlying EBITDA and Margin1) ¤ in millions 866.8 912.3 819.6 929.2 1,172.7 1,334.7 161.1 172.6 162.3 186.8 263.2 325.4 845.7 887.3 791.6 891.2 1,114.8 1,300.3 19.0 19.5 20.5 21.0 23.6 25.0 1,500 400 30 1,250 300 27 1,000 200 24 750 100 21 500 0 18 2012 2013 2013 2014 2015 2016 2012 2013 2013 2014 2015 2016 Continued operations Continued operations Q Order intake Q Underlying EBITDA in millions of ¤ QSales revenue Underlying EBITDA margin in % Key Figures All figures are given in millions of ¤ according 2016 2015 2014 2013 2013 2012 to the IFRS, unless otherwise specified restated Order intake, sales revenue and earnings Order intake 1,334.7 1,172.7 929.2 819.6 912.3 866.8 Sales revenue 1,300.3 1,114.8 891.2 791.6 887.3 845.7 Underlying EBITDA1) 325.4 263.2 186.8 162.3 172.6 161.1 Underlying EBITDA1) as a % of sales revenue 25.0 23.6 21.0 20.5 19.5 19.0 Relevant net profit for continuing operations2) 132.6 107.4 66.1 59.2 – – Relevant net profit2) 132.6 107.4 73.7 64.8 64.8 63.0 Research and development costs 59.4 52.5 43.63) 47.7 53.8 49.0 Financial data per share4) Earnings per share continued operations2) per ordinary share (in ¤) 1.93 1.57 0.96 0.86 – – per preference share (in ¤) 1.94 1.58 0.97 0.87 – – Earnings per share2) per ordinary share (in ¤) 1.93 1.59 1.07 0.95 0.95 0.92 per preference share (in ¤) 1.94 1.60 1.08 0.96 0.96 0.93 Dividends per ordinary share (in ¤) 0.455) 0.37 0.26 0.25 0.25 0.23 per preference share (in ¤) 0.465) 0.38 0.27 0.26 0.26 0.24 Balance
    [Show full text]
  • QIAGEN N.V., Venlo, Niederlande
    QIAGEN N.V., Venlo, Niederlande Einladung zur ordentlichen Hauptversammlung Wir laden hiermit unsere Aktionäre zur ordentlichen Hauptversammlung der QIAGEN N.V. am Dienstag, den 30. Juni 2020 um 15.00 Uhr am Sitz der Gesellschaft, Hulsterweg 82, 5912 PL Venlo, Niederlande, ein. Aufgrund der Corona Pandemie und um unsere Aktionäre und alle anderen Teilnehmer der ordentlichen Hauptversammlung bestmöglich zu schützen, findet die Hauptversammlung ausschließlich in virtueller Form statt und wird in englischer Sprache abgehalten. Aktionären wird folglich kein physischer Zutritt zur Hauptversammlung gewährt. Die Versammlung wird live per audio webcast auf der Internetseite der Gesellschaft unter www.qiagen.com übertragen. Hierfür ist eine vorherige Anmeldung nicht notwendig. Zusätzlich zu den jährlich wiederkehrenden Tagesordnungspunkten wird die ordentliche Hauptversammlung in diesem Jahr auch eine Reihe von Tagesordnungspunkten umfassen, die sich auf das empfohlene Angebot der Quebec B.V, einer hundertprozentigen Tochtergesellschaft von Thermo Fisher Scientific Inc., für den Erwerb aller Stammaktien der Gesellschaft, einschließlich aller zum Zeitpunkt der Abwicklung des Angebots bestehenden Nebenrechte, insbesondere der Gewinnanteilsberechtigung, gegen Zahlung einer unverzinslichen Bargegenleistung in Höhe von EUR 39,00 je Stammaktie. Die Fassung des Back-End-Beschlusses (Tagesordnungspunkt 18) ist eine der Angebotsbedingungen. Heute wurden die Angebotsunterlage und die gemeinsame begründete Stellungnahme von QIAGEN und dem Vorstand und dem Aufsichtsrat zum Übernahmeangebot veröffentlicht. Wir empfehlen Ihnen eindringlich, diese Dokumente sorgfältig durchzulesen, da sie wichtige Informationen über das Angebot enthalten. Die Tagesordnung der ordentlichen Hauptversammlung der Gesellschaft mit den Vorschlägen von Vorstand und Aufsichtsrat lautet wie folgt: Jährliche wiederkehrende Tagesordnungspunkte 1. Eröffnung 2. Bericht des Vorstands über das am 31. Dezember 2019 abgelaufene Geschäftsjahr 3.
    [Show full text]
  • Eurex Circular 043/14
    eurex circular 043/14 Date: 6 March 2014 Recipients: All Trading Participants of Eurex Deutschland and Eurex Zürich and Vendors Authorized by: Thomas Book Action required A. Single Stock Futures: Introduction of SSFs on Belgian, French, German, Italian, Spanish and Swiss underlyings; B. Equity options: Introduction of equity options on CompuGroup Medical AG, Flughafen Wien AG Inhaber-Aktien o.N. and Nemetschek AG Inhaber-Aktien o.N. Contact: Derivatives Trading Operations, T +49-69-211-1 12 10, Michael Durica, T +49-69-211-1 59 23 Content may be most important for: Attachments: Ü All departments 1. Updated Annexes A and B of the Contract Specifications for Futures Contracts and Options Contracts at Eurex Deutschland and Eurex Zürich 2. Market Maker Obligations (excerpt) Summary: The Management Board of Eurex Deutschland and the Executive Board of Eurex Zürich AG took the following decisions with effect from 10 March 2014: 1. Introduction of Single Stock Futures on Beneteau S.A. Actions Port. EO -,10, Société Foncière Lyonnaise SA Actions Port. EO 2, Carl Zeiss Meditec AG, Dt. Annington Immobilien SE Namens-Aktien o.N., CompuGroup Medical AG, CANCOM SE, Almirall S.A. Acciones Port. EO -,12, GameLoft SE Actions Port. EO 0,05, Helvetia Holding AG, KBC Ancora Actions au Port. o.N, LEG Immobilien AG, LPKF Laser & Electronics AG, C.M.B. (Cie Maritime Belge) SA Actions Nouvelles au Port.o.N., Nemetschek AG Inhaber-Aktien o.N., Norma Group SE, Telefonica Deutschland Holding, Swiss Prime Site AG, Sartorius AG, Temenos Group AG and Yoox S.p.A. Azioni nom.
    [Show full text]
  • THOUGRT Am SENATE REFUSES a TARIFF on OIL for FIFTH TIME
    THE WEATHER NET PRESS RUN Porecaat by i>. & Weatiiw Boreau, . Hartford. AVERAGE DAILV CIRCDIATION for tile Montii of February, 19S0 Fair and much colder tonfgffat; Saturday increasing cloudiness and 5 , 5 0 3 coatina^ cold. Memben of the AnOlt Biurcan of Clrcnlatloaa PRICE THREE CENTS SOUTH MANCHESTER, CONN., F*RH)AY, MARCH 21, 1930. TWENTY PAGES VOL. XLIV., NO. 146. (Classified Advertising on Page 18) FAMOUS FIDDLER AS “SILVER BULLET” TUNED UP AT DAYTONA BEACH PfflSONUQUOR SENATE REFUSES ALCOm PLEA SAVED BY WIFE FOR RECORD DASH » THOUGRT am FOR RETURN OF Mellie Dunham Gets Out ofj A TARIFF ON OIL Blazing Home in Time But} " m His Prizes and Relics Are| INDEmHERE CONViaSOX’d Burned. i Norway, Maine, March 21— 'M FOR FIFTH TIME (AP) —^Mellie Dunham, famous Arthur Aitken Dies Sudden­ fiddler was saved by his aged 5#^ Lalone, Moulthrope and Lan­ helpmate, “Gram,” from a fire which destroyed their century ly After Drinking Hooch, Watson, Republican Leader, dry to Be Brought Back old farmhouse on Crockett’s JOBLESS SnUATION Ride today, but his many “fid­ But Inyestigation Shows Announces That Upp^r X dles” and prizes, relics and , To This State to Face antiques were lost. , -V BAD AS IN ’14 “Gram,” awoke at 2 a. m. to find a room adjoining their bed­ Booze Not Direct Cause. House Shall Stay In Ses­ ^ Other Charges. room ablaze. She awakened Mellie and three grandchildren Arthur Aitken, unmarried, an out- i So Says New York State Of- sion Tomorrow Until It in smother room. side labor time keeper employed Hartford, Conn., March 21.—(AP) Assisted by “Gram,” Mellie —State’s Attorney Hugh M.
    [Show full text]
  • Annual Report 2017/18 of the ZEISS Group
    Annual Report 2017/18 ZEISS Group Financial Highlights (IFRSs) 2017/18 2016/17 2015/16 € m % € m % € m % Revenue 5,817 100 5,348 100 4,881 100 » Germany 610 10 621 12 612 13 » Other countries 5,207 90 4,727 88 4,269 87 Research and development expenses 642 11 552 10 436 9 EBIT 772 13 770 14 615 13 Consolidated profit/loss 535 9 561 10 404 8 Cash flows from operating activities 576 445 425 Cash flows from investing activities -334 -642 -357 Cash flows from financing activities -89 258 -207 Total assets 7,903 100 7,317 100 5,658 100 Property, plant and equipment 1,028 13 973 13 979 17 » Capital expenditures 244 183 154 » Amortization, depreciation and impairment 164 160 155 Inventories 1,391 18 1,275 17 1,118 20 Equity 3,763 48 3,429 47 1,416 25 Net liquidity 2,120 1,986 568 Employees as of 30 September 29,309 26,945 25,433 » Germany 12,067 11,339 10,770 » Other countries 17,242 15,606 14,663 Further information at: www.zeiss.com/annualreport Content Fiscal Year 2017/18 Foreword from the Executive Board 4 Expert Interview 6 Fiscal Year Highlights 10 Represented Worldwide 12 Future-Shaping Segments 13 Responsible Behavior 14 Ownership Structure 15 Report of the Supervisory Board 16 Supervisory Board of Carl Zeiss AG 18 Corporate Governance 18 Group Management Report The ZEISS Group 20 Report on Economic Position 22 Non-Financial Key Performance Indicators 31 Risk and Opportunity Report 34 Subsequent Events 38 Report on Expected Developments 39 Consolidated Financial Statements Consolidated Income Statement 42 Consolidated Statement of Comprehensive
    [Show full text]
  • Name Symbol Margin Listing 3M Co MMM.N 5% NYSE Abbott
    Name Symbol Margin Listing 3M Co MMM.N 5% NYSE Abbott Laboratories ABT.N 5% NYSE AbbVie Inc ABBV 5% NYSE Accenture Plc ACN 5% NYSE Air Products & Chemicals Inc APD 5% NYSE Alibaba BABA.N 5% NYSE Allergan AGN.N 5% NYSE Allstate ALL.N 5% NYSE Altria Group MO.N 5% NYSE American Electric ÆP.N 5% NYSE American Express AXP.N 5% NYSE American International Group AIG.N 5% NYSE American Tower Corp AMT 5% NYSE Anthem ANTM.N 5% NYSE Aon Plc AON 5% NYSE Archer-Daniels Mid ADM.N 5% NYSE At&T T.N 5% NYSE Autozone AZO.N 5% NYSE AvalonBay Communities Inc AVB 5% NYSE Bank Of America BAC.N 5% NYSE Bank Of New York BK.N 5% NYSE Baxter International BAX.N 5% NYSE BB&T Corporation BBT.N 5% NYSE Becton Dickinson & Co BDX 5% NYSE Berkshire Hathaway Inc - Class B BRKB 5% NYSE Best Buy BBY.N 5% NYSE Blackrock BLK.N 5% NYSE Blackstone Group Inc BX 5% NYSE Bœin BA.N 5% NYSE Boston Scientific BSX.N 5% NYSE Bristol-Myer Squiib BMY.N 5% NYSE Cabot Oil & Gas Corp COG 5% NYSE Capital One COF.N 5% NYSE Cardinal Health Inc CAH 5% NYSE Carnival CCL.N 5% NYSE Caterpillar CAT.N 5% NYSE Centene Corporation CNC.N 5% NYSE CenturyLink Inc CTL 5% NYSE Chevron CVX.N 5% NYSE Chubb CB.N 5% NYSE Cigna CI.N 5% NYSE Citigroup C.N 5% NYSE Clorox Company CLX 5% NYSE Coca-Cola KO.N 5% NYSE Colgate-Palmo CL.N 5% NYSE Comerica CMA.N 5% NYSE Concho Resources Inc CXO 5% NYSE Conoco Phillips COP.N 5% NYSE Consolidated Edison Inc ED 5% NYSE Constellation Brands Inc STZ.N 5% NYSE Corning GLW.N 5% NYSE Crown Castle Intl Corp CCI 5% NYSE CSX Corporation CSX.N 5% NYSE Cummins Inc CMI 5% NYSE CVS
    [Show full text]
  • EXTEL 2018 Investor Relations Rankings for Germany
    EXTEL 2018 Investor Relations rankings for Germany June 2018 1. EXECUTIVE OVERVIEW & COMMENTARY This year marks the 13th Anniversary of the partnership between DIRK – Deutsche Investor Relations Verband - and Extel, an Institutional Investor Company. Every year, this successful collaboration produces the highly lauded Investor Relations Study, which takes its data from Extel’s comprehensive annual Pan-European Survey. The survey measures IR excellence and includes insightful views and trend information from investment professionals globally who are either invested in or cover the German equity market. The results of the study form the basis of the ‘Deutsche Investor Relations Preis’, presented during the DIRK annual conference in Frankfurt in June 2018. As part of its annual Pan-European Survey, year. The leading MDAX IR Professional Extel undertook this study from 14th March to was Burkhard Sawazki of LEG Immobilien 27th April, 2018; seeking ratings and rankings where 136 individuals received for IR excellence, at a company level and nominations. separately for IR professionals. From the In the SDAX category Hapag-Lloyd moved overall sector contributions, we derived up from 11th last year to 1st place. For the distinct rankings for the main German equity individual IR Professional ranking in SDAX, indices constituents – DAX30, MDAX, SDAX and Stephan Haas of SAF-HOLLAND was TecDAX. The study was undertaken almost ranked 1st, out of 61 individuals receiving exclusively through direct online votes. nominations. Telefonica Deutschland held on to top Since the beginning of the Extel and DIRK’s spot as the highly regarded TecDAX partnership in 2006, responses have increased company for IR.
    [Show full text]
  • FACTSHEET - AS of 27-Sep-2021 Deutschland Ethik 30 Aktienindex
    FACTSHEET - AS OF 27-Sep-2021 Deutschland Ethik 30 Aktienindex HISTORICAL PERFORMANCE 300 250 200 150 100 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Deutschland Ethik 30 Aktienindex CHARACTERISTICS ISIN / WKN DE000SLA8ET8 / SLA8ET Base Value / Base Date 100 Points / 31.12.2013 Bloomberg / Reuters DETHIP30 Index / .DETHIP30 Last Price 290.19 Index Calculator Solactive AG Dividends Not included (Price index) Index Type Equity Calculation 08:00am to 06:00pm (CET), every 15 seconds Index Currency EUR History Available daily back to 31.12.2013 Index Members 30 FACTSHEET - AS OF 27-Sep-2021 Deutschland Ethik 30 Aktienindex STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -2.05% -0.50% 4.31% 18.22% 8.80% 54.20% Performance (p.a.) - - - - - 5.75% Volatility (p.a.) 12.00% 11.76% 11.67% 14.61% 12.36% 18.47% High 296.27 298.82 298.82 298.82 298.82 298.82 Low 282.92 282.92 278.19 225.13 261.73 158.75 Sharpe Ratio -1.81 -0.12 0.81 1.30 1.02 0.34 Max. Drawdown -4.51% -5.32% -5.32% -11.56% -5.32% -41.72% VaR 95 \ 99 -23.1% \ -40.4% -28.6% \ -53.0% CVaR 95 \ 99 -36.1% \ -61.6% -45.3% \ -74.2% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES EUR 100.0% DE 100.0% TOP COMPONENTS AS OF 27-Sep-2021 Company Ticker Country Currency Index Weight (%) SAP SE SAP GY Equity DE EUR 9.88% SIEMENS AG SIE GY Equity DE EUR 9.79% ALLIANZ SE ALV GY Equity DE EUR 8.98% DEUTSCHE POST AG DPW GY Equity DE EUR 7.74% ADIDAS AG ADS GY Equity DE EUR 6.21% LEG IMMOBILIEN SE LEG GY Equity DE EUR 6.03% TELEFONICA DEUTSCHLAND HOLDING AG O2D GY Equity DE EUR
    [Show full text]
  • FTSE Publications
    2 FTSE Russell Publications FTSE EDHEC-Risk Efficient 19 August 2021 Eurozone Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 1&1 AG 0.12 GERMANY Continental 0.79 GERMANY Henkel KG Pref 0.21 GERMANY A2A 0.25 ITALY Covestro AG 0.22 GERMANY Henkel Kgaa ORD 0.1 GERMANY Aalberts NV 0.31 NETHERLANDS Covivio 0.24 FRANCE Hera 0.19 ITALY ABN AMRO Bank NV 0.45 NETHERLANDS Credit Agricole 0.18 FRANCE Hermes International S.C.A. 0.86 FRANCE Acciona S.A. 0.33 SPAIN Cts Eventim 0.22 GERMANY Hochtief 0.15 GERMANY Accor 0.15 FRANCE Daimler AG 0.17 GERMANY Huhtamaki 0.2 FINLAND Ackermans & Van Haaren 0.66 BELGIUM Danone 0.64 FRANCE Iberdrola 0.1 SPAIN ACS Actividades Cons y Serv 0.13 SPAIN Dassault Aviation S.A. 0.14 FRANCE Icade 0.42 FRANCE Adidas 0.11 GERMANY Dassault Systemes 0.15 FRANCE Iliad 0.39 FRANCE Adyen 0.46 NETHERLANDS Delivery Hero SE 0.35 GERMANY IMCD NV 0.23 NETHERLANDS Aegon NV 0.18 NETHERLANDS Deutsche Bank 0.16 GERMANY Imerys 0.24 FRANCE Aena SME SA 0.23 SPAIN Deutsche Boerse 0.25 GERMANY Inditex 0.14 SPAIN Aeroports de Paris 0.28 FRANCE Deutsche Lufthansa AG 0.53 GERMANY Infineon Technologies AG 0.36 GERMANY Ageas 0.43 BELGIUM Deutsche Post 0.14 GERMANY ING Group CVA 0.18 NETHERLANDS Ahold Delhaize 0.36 NETHERLANDS Deutsche Telekom 0.12 GERMANY Inmobiliaria Colonial S.A.
    [Show full text]
  • FTSE Developed Europe
    2 FTSE Russell Publications 19 August 2021 FTSE Developed Europe Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 1&1 AG 0.01 GERMANY Avast 0.03 UNITED Cnp Assurance 0.02 FRANCE 3i Group 0.14 UNITED KINGDOM Coca-Cola HBC AG 0.06 UNITED KINGDOM Aveva Group 0.05 UNITED KINGDOM A P Moller - Maersk A 0.1 DENMARK KINGDOM Coloplast B 0.19 DENMARK A P Moller - Maersk B 0.15 DENMARK Aviva 0.19 UNITED Colruyt 0.03 BELGIUM A2A 0.03 ITALY KINGDOM Commerzbank 0.07 GERMANY Aalberts NV 0.05 NETHERLANDS AXA 0.43 FRANCE Compagnie Financiere Richemont SA 0.55 SWITZERLAND ABB 0.51 SWITZERLAND B&M European Value Retail 0.06 UNITED Compass Group 0.33 UNITED KINGDOM ABN AMRO Bank NV 0.04 NETHERLANDS KINGDOM BAE Systems 0.21 UNITED Acciona S.A. 0.03 SPAIN Continental 0.14 GERMANY KINGDOM Accor 0.06 FRANCE ConvaTec Group 0.05 UNITED Baloise 0.06 SWITZERLAND Ackermans & Van Haaren 0.03 BELGIUM KINGDOM Banca Mediolanum 0.02 ITALY ACS Actividades Cons y Serv 0.06 SPAIN Covestro AG 0.1 GERMANY Banco Bilbao Vizcaya Argentaria 0.36 SPAIN Adecco Group AG 0.09 SWITZERLAND Covivio 0.04 FRANCE Banco Santander 0.58 SPAIN Adevinta 0.04 NORWAY Credit Agricole 0.14 FRANCE Bank Pekao 0.03 POLAND Adidas 0.63 GERMANY Credit Suisse Group 0.22 SWITZERLAND Bankinter 0.03 SPAIN Admiral Group 0.08 UNITED CRH 0.35 UNITED Banque Cantonale Vaudoise 0.02 SWITZERLAND KINGDOM KINGDOM Barclays 0.35 UNITED Adyen 0.62 NETHERLANDS Croda International 0.12 UNITED KINGDOM KINGDOM Aegon NV 0.06 NETHERLANDS Barratt Developments 0.09 UNITED Cts Eventim 0.03 GERMANY Aena SME SA 0.1 SPAIN KINGDOM Cyfrowy Polsat SA 0.02 POLAND Aeroports de Paris 0.03 FRANCE Barry Callebaut 0.07 SWITZERLAND Daimler AG 0.66 GERMANY Ageas 0.09 BELGIUM BASF 0.64 GERMANY Danone 0.37 FRANCE Ahold Delhaize 0.26 NETHERLANDS Bayer AG 0.53 GERMANY Danske Bank A/S 0.1 DENMARK AIB Group 0.02 IRELAND Bechtle 0.04 GERMANY Dassault Aviation S.A.
    [Show full text]
  • Cboe Germany Mid Cap 50 Index BDEM50P
    Cboe Germany Mid Cap 50 Index BDEM50P Page 1 August 2021 Cboe Exchange The Cboe DEM 50 index aims to be comprised of the next 50 largest German issuers i.e. companies ranked 31 to 80 by their market capitalisation. The index base level is 10,000 as of December 31st, 2010. This is a price return index. Objective The index is designed for use in the creation of index tracking funds, derivatives and as a performance benchmark. Investability Liquidity Transparency Availability Stocks are selected and Stocks are screened to Uses a transparent, rules-based Calculation is based on weighted to ensure that the ensure that the index is construction process. Index price and total return index is investable. tradable. Rules are freely available on the methodologies, both real cboe.com/europe/indices -time, intra-second and website. end of day. Statistics Index ISIN Ticker RIC Currency Cboe Germany Mid Cap 50 DE000SLA2QA5 BDEM50P .BDEM50P EUR Cboe Germany Mid Cap 50 - net DE000SLA2QJ6 BDEM50N .BDEM50N EUR Volatility Volatility (1y) 0.1454 Returns(%) 1M 3M 6M YTD 1Y 3Y 5Y BDEM50P 1.05 3.79 12.39 14.97 29.39 25.62 63.29 BDEM50N 1.05 4.25 13.52 16.17 31.1 31.02 75.68 Top 5 Performers Country 1 month return % WACKER CHEMIE AG GERMANY 20.37 EVOTEC SE GERMANY 20.14 COMPUGROUP MEDICAL SE & CO KGA GERMANY 16.59 HYPOPORT SE GERMANY 15.26 HELLOFRESH SE GERMANY 14.98 Historical Performance Chart 250% 200% 150% 100% 50% 0% 2011 2013 2014 2016 2017 2018 2020 2021 Cboe Germany Mid Cap 50 (EUR) Cboe Germany 30 (EUR) Cboe Germany Small Cap 50 (EUR) Cboe.com | ©Cboe | /CboeGlobalMarkets | /company/cboe © 2021 Cboe Exchange, Inc.
    [Show full text]
  • Wcra Annual Report 2016
    WCRA ANNUAL REPORT 2016 Meeting Washington’s Affordable Housing Needs Through Partnership Washington Community Reinvestment Association MISSION STATEMENT To be a catalyst for the creation and preservation of affordable housing in Washington state. To expand resources for real estate based community development in Washington state. To be a voice for its member financial institutions on affordable housing and community development issues. To provide a dynamic risk sharing vehicle to maximize private investment in community development throughout Washington state. To operate within a strategic and financially prudent structure. To work with public sector entities to promote public/private partnerships that achieve maximum leverage of public dollars. To provide value to its members and the communities they serve that will generate and sustain support for WCRA's long term operation and success. TABLE OF CONTENTS Featured Projects Lilac Place ................................................................................................................................................4 Glennwood Townhomes .......................................................................................................................6 Kirkland Avenue Townhomes ..............................................................................................................8 Valle Lindo II ..........................................................................................................................................10 Galbraith Gardens ................................................................................................................................11
    [Show full text]